Patients over 40 years old with precursor T-cell lymphoblastic lymphoma have different prognostic factors comparing to the youngers

Meng, Di; Zhang, Xudong; Yang, Zhenzhen; Wu, Shihao; Ma, Mijing; Li, Zhaoming; Chang, Yu; Wang, Xinhua; Li, Ling; Li, Xin; Zhang, Mingzhi; Chen, Qingjiang

doi:10.1038/s41598-018-19565-x

Cited by 12 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our previous studies, we found some prognostic clinical indicators in T-LBL (14,15). We also found that the novel mutation in CDC27, which ranked highly in the samples (16).…”

Section: Introductionmentioning

confidence: 50%

CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma

Song

et al. 2020

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

T-lymphoblastic lymphoma (T-LBL) is a rare hematological malignancy with highly aggressive, unique clinical manifestations, and poor prognosis. Cell division cycle 27 (CDC27) was previously reported to be a significant subunit of the anaphase-promoting complex/cyclosome. However, the specific functions and relevant mechanisms of CDC27 in T-LBL remain unknown. Through immunohistochemistry staining, we identified that CDC27 was overexpressed in T-LBL tissues and related to tumor progression and poor survival. Functional experiments demonstrated that CDC27 promoted proliferation in vivo and in vitro. Further experiment suggested the role of CDC27 in facilitating G1/S transition and promoting the expression of Cyclin D1 and CDK4. Then the effect of CDC27 in inhibiting apoptosis was also identified. Furthermore, we found a positive correlation between the expression of CDC27 and Programmed death ligand-1 (PD-L1) by immunohistochemistry staining. The interaction between CDC27 and PD-L1 was also proved by western blot, luciferase gene reporter assay and immunofluorescence. Taken together, our results showed that CDC27 contributes to T-LBL progression and there is a positive correlation between PD-L1 and CDC27, which offers novel perspectives for future studies on targeting CDC27 in T-LBL.

show abstract

“…In our previous studies, we found some prognostic clinical indicators in T-LBL (14,15). We also found that the novel mutation in CDC27, which ranked highly in the samples (16).…”

Section: Introductionmentioning

confidence: 50%

CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma

Song

et al. 2020

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…All patients received at least two cycles of chemotherapy. Among these patients, 37 (49.3%) patients were given Hyper‐CVAD/MA regimen, and 45.3% of these patients were administrated with the modified BFM90 regimen, as shown in the study by Dong et al . The remaining four patients were treated with CHOP‐based (cyclophosphamide, epirubicin, vincristine and prednisone) regimen.…”

Section: Resultsmentioning

confidence: 97%

Complete Blood Count Score Model Integrating Reduced Lymphocyte-Monocyte Ratio, Elevated Neutrophil-Lymphocyte Ratio, and Elevated Platelet-Lymphocyte Ratio Predicts Inferior Clinical Outcomes in Adult T-Lymphoblastic Lymphoma

Feng

et al. 2019

The Oncologist

Self Cite

View full text Add to dashboard Cite

Background T‐lymphoblastic lymphoma (T‐LBL) is a highly aggressive neoplasm of lymphoblasts of T‐cell origin. Although promising improvements have been recently achieved, one third of patients experience relapse or refractory T‐LBL. Therefore, optimal strategies for identifying high‐risk patients are urgently needed. Materials and Methods In the present study, 75 newly diagnosed adult patients (aged ≥15 years) with T‐LBL were identified and the predictive value of complete blood count (CBC) abnormalities, including lymphocyte‐monocyte ratio (LMR), neutrophil‐lymphocyte ratio (NLR), and platelet‐lymphocyte ratio (PLR) on clinical outcomes, was analyzed. Results Using the receiver operating characteristic curve to determine the best cutoff values based on survival, it was found that patients with T‐LBL with LMR ≤2.8, NLR ≥3.3, and PLR ≥200 had both inferior progression‐free survival (PFS) and inferior overall survival (OS), in which the differences were much more remarkable in the international prognostic index score 0–2 subgroup. In the multivariable analysis, NLR ≥3.3 together with age >40 years and central nervous system (CNS) involvement were identified to be independently associated with shortened PFS, whereas PLR ≥200 and CNS involvement were identified to be independent risk factors for OS. LMR, NLR, and PLR were integrated to generate a “CBC score” model, which well separated adult patients with T‐LBL into three risk groups, and the 3‐year OS was 84%, 53%, and 30% for low‐, intermediate‐, and high‐risk patients, respectively. Conclusion Overall, a “CBC score” model was initially promoted for stratification in adult patients with T‐LBL using simple, widely available, and easy to interpret parameters in the largest adult T‐LBL cohort to date. Implications for Practice Optimal strategies for identifying high‐risk patients with T‐lymphoblastic lymphoma (T‐LBL) are urgently needed. In the largest adult T‐LBL cohort to date, simple, inexpensive, widely available parameters were applied and revealed that patients with lymphocyte‐monocyte ratio (LMR) ≤2.8, neutrophil‐lymphocyte ratio (NLR) ≥3.3, and platelet‐lymphocyte ratio (PLR) ≥200 had both inferior progression‐free survival and inferior overall survival (OS), in which the differences were much more remarkable in the international prognostic index score 0–2 subgroup. LMR, NLR, and PLR were integrated to generate a “complete blood count score” model, in which the 3‐year OS was 84%, 53%, and 30% for low‐, intermediate‐, and high‐risk patients, respectively.

show abstract

“…La LLA exhibe típicamente inmunofenotipos de células precursoras, se clasifican principalmente en dos subtipos LLA-T (CD3+) y LLA-B (CD19/CD20+) (25), de esta forma, la detección de la EMR por CMF en un análisis de 1 célula leucémica por 105 leucocitos (26,27) donde la expresión de antígenos como CD10, CD3, CD7, CD19, CD20, CD34, CD38, CD45, cCD3+ y TdT en células leucémicas puede predecir la aparición de la EMR (24,(27)(28)(29). Esto difiere según el factor de riesgo como la edad avanzada, el recuento de leucocitos, alteraciones genéticas y la respuesta a la quimioterapia, lo cual, aumenta la probabilidad de recaída durante los 2 años posteriores al diagnóstico, con una tasa de supervivencia inferior del 25% (9,10,25,30). Por esta razón, el diseño de un panel de anticuerpos monoclonales es fundamental para la identificación de blastos y sus características fenotípicas relevantes, que dan resultados significativos en la detección de la EMR.…”

Section: Generalidadesunclassified

“…La muestra de médula ósea (MO) es la más utilizada para el diagnóstico, clasificación y detección de la EMR en la LLA (10,16,17,(25)(26)(27)31); sin embargo, estudios realizados usando sangre periférica, lo cual, demostraron que los niveles de EMR en sangre en pacientes diagnosticados con LLA-T eran compatibles o 1 log más bajo que en MO y en pacientes con LLA-B se detectaron en sangre 1 a 3 log más bajos que en MO (16,17,(31)(32)(33). En consecuencia, lo más conveniente para monitorear la enfer-medad mínima residual independiente del origen T o B, es la muestra de médula ósea o aspirado medular, donde se recomienda recolectar un volumen entre 2 a 5 mL para examinar >5x10 6 células por citometría de flujo y obtener un rango de sensibilidad 10 -4 células blásticas aberrantes (16,34).…”

Section: Muestras óPtimasunclassified

Enfermedad mínima residual por citometría de flujo en pacientes con leucemia linfoblástica aguda

Hernandez

Bernal-Estévez²,

Baquero

2022

nova

View full text Add to dashboard Cite

Antecedentes. La citometría de flujo (CMF) es una técnica que permite el análisis multiparamétrico de poblaciones celulares, siendo esencial en la investigación biomédica y como herramienta diagnóstica. Esta técnica rápida tiene una alta sensibilidad, evaluandocaracterísticas en la población de interés como es el caso del tamaño, granularidad, complejidad del citoplasma celular y proteínas de que permiten la clasificación fenotípica y funcional de un gran número de células. Por estas razones, esta técnica ha adquiridoimportancia en el diagnóstico y seguimiento de enfermedades y anomalías hematológicas, como leucemias, síndromes mielodisplásicos y síndromes mieloproliferativos, entre otras. Objetivo. La presente revisión se enfoca en los avances en la implementación de la CMF en la Enfermedad Mínima Residual (EMR) presente en la Leucemia Linfoblástica Aguda (LLA), la cual es una población mínima leucémica que se detecta en un paciente después de suministrar un tratamiento oncológico, donde se evalúa su eficacia, el riesgo de una recaída y el proceso de remisión completa. Metodología. Se realiza una revisión no sistemática deliteratura en bases de datos, de los últimos 15 años, donde evalúen las implicaciones del uso de citometría de flujo en la EMR, de esta revisión se extraen aspectos relevantes al momento de emplear la CMF para el diagnóstico y seguimiento de pacientes con leucemias. Resultados. La CMF es una técnica muy versátil e importante para el diagnóstico y seguimiento de la EMR por su alta sensibilidad para la detección de bajos números de células resistentes a la terapia. Adicionalmente se muestra la importancia de la estandarización de protocolos como EUROFLOW para un adecuado procesamiento y análisis clínico de las muestras de pacientes.

show abstract

Patients over 40 years old with precursor T-cell lymphoblastic lymphoma have different prognostic factors comparing to the youngers

Cited by 12 publications

References 27 publications

CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma

CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma

Complete Blood Count Score Model Integrating Reduced Lymphocyte-Monocyte Ratio, Elevated Neutrophil-Lymphocyte Ratio, and Elevated Platelet-Lymphocyte Ratio Predicts Inferior Clinical Outcomes in Adult T-Lymphoblastic Lymphoma

Enfermedad mínima residual por citometría de flujo en pacientes con leucemia linfoblástica aguda

Contact Info

Product

Resources

About